YM BioSciences

YM BioSciences is a product development company. Our focus is to advance cancer products along the regulatory and clinical pathways towards commercial approval. YMB does not conduct basic research; rather, our product portfolio is established through a process of careful, rational selection of therapeutics produced in research institutions around the globe. We have one of the broadest oncology portfolios in North America, diversified across technologies, targets and stages of development, to avoid reliance on a single product or platform. YMB is cancer focused. Our current products target solid tumours, which comprise most common types of cancer, and cancer pain. Our current clinical emphasis is on metastatic breast cancer, advanced prostate cancer, unresectable head & neck cancer, specific types of brain tumours, and cancer pain. The large markets for cancer products, combined with typically lower-cost and rapid Phase I and II clinical trials, make this a compelling area on which to focus from a business perspective. YMB currently has four different anti-cancer compounds in clinical development, including tesmilifene, which has completed a 305-patient Phase III clinical trial with positive results. Our business model is to eventually co-develop or partner with pharmaceutical multinationals to manufacture and market our products and offset the cost of pivotal trials. We believe this balanced approach provides the best risk/reward profile for our shareholders.

Contact Details: 5045 Orbitor DriveBuilding 11, Suite 400 Mississauga Ontario L4W 4Y4 Canada Tel: 905.629.9761 Fax: 905.629.4959 Email: ir@ymbiosciences.com WWW: www.ymbiosciences.com/

Loading...

BioNews Results for YM BioSciences:
Ym Biosciences Inc.: Ym Biosciences Reports Fiscal Year End 2008	FinanzNachrichten.de:  Sep 22 2008 6:05AM Matching: ym biosciences
YM Biosciences Reports Fiscal Year End 2008 Operational and Financial Results	Pharma Live:  Sep 22 2008 8:21PM Matching: ym biosciences
YM BioSciences FY net loss narrows to C$14.9 mln vs C$31.7 mln	Forbes.com:  Sep 22 2008 9:25AM Matching: ym biosciences
YM BioSciences FY net loss narrows to C$14.9 mln vs C$31.7 mln	Quote.com Canada:  Sep 22 2008 8:36AM Matching: ym biosciences
YM BioSciences FY net loss narrows to C$14.9 mln vs C$31.7 mln	Interactive Investor International:  Sep 22 2008 8:25AM Matching: ym biosciences
Promote your company here: BioNewsCast - Press Release Distribution	→View more YM BioSciences news.

YM BioSciences (YMI) Financial information Links from Barchart
YMI Quote from from Barchart.com
YMI Chart from from Barchart.com
YMI Profile from from Barchart.com
YMI Opinion from from Barchart.com
→View more YM BioSciences finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 258 times since April 2007, the link to the organisation's website has been followed 58 times

Recent Search Terms used to find this page: ym biosciences | YMBiosciences.com | YMBiosciences.com | YM biosciences | .

Search for more companies in Mississauga

Search for more companies in Ontario

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for YM BioSciences